-
公开(公告)号：US07326569B2
公开(公告)日：2008-02-05
申请号：US10236051
申请日：2002-09-03
CPC分类号： B82Y15/00 , C07K16/2896 , C07K2319/00 , C07K2319/033 , C07K2319/32 , G01N33/6872 , G01N2333/70596 , G01N2400/50 , G01N2800/26
摘要： This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders with CD14 mediated cell activation, such as sepsis.
摘要翻译： 本发明提供产生抑制CD14介导的细胞活化的单克隆抗体的杂交瘤细胞系。 也提供了由这些细胞系产生的单克隆抗体。 该抗体可用于检测样品中细胞表面和可溶性CD14的存在。 进一步提供由上述单克隆抗体产生的嵌合和CDR移植的抗体。 提供含有上述生物组合物的药物组合物。 这些可用于治疗和预防CD14介导的细胞活化如败血症的疾病。
-
2.发明授权公开(公告)号：US06444206B1
公开(公告)日：2002-09-03
申请号：US09170769
申请日：1998-10-13
IPC分类号： A61K39395
CPC分类号： B82Y15/00 , C07K16/2896 , C07K2319/00 , C07K2319/033 , C07K2319/32 , G01N33/6872 , G01N2333/70596 , G01N2400/50 , G01N2800/26
摘要： This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders with CD14 mediated cell activation, such as sepsis.
摘要翻译： 本发明提供产生抑制CD14介导的细胞活化的单克隆抗体的杂交瘤细胞系。 也提供了由这些细胞系产生的单克隆抗体。 该抗体可用于检测样品中细胞表面和可溶性CD14的存在。 进一步提供由上述单克隆抗体产生的嵌合和CDR移植的抗体。 提供含有上述生物组合物的药物组合物。 这些可用于治疗和预防CD14介导的细胞活化如败血症的疾病。
-
3.发明授权
公开(公告)号：US5820858A
公开(公告)日：1998-10-13
申请号：US373297
申请日：1995-01-23
IPC分类号： G01N33/53 , A61K39/395 , A61P31/04 , A61P43/00 , C07K16/28 , C12N1/21 , C12N5/10 , C12N15/02 , C12N15/09 , C12P21/08 , G01N33/577 , C07H21/04 , C07K16/00 , G01N33/567
CPC分类号： B82Y15/00 , C07K16/2896 , G01N33/6872 , C07K2319/00 , C07K2319/033 , C07K2319/32 , G01N2333/70596 , G01N2400/50 , G01N2800/26
摘要： This invention provides monoclonal antibodies that bind to the cell surface CD14 receptor and soluble CD14 receptor. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent LPS-associated disorders, such as sepsis.
摘要翻译： PCT No.PCT / US94 / 05898 Sec。 371日期1995年1月23日 102（e）日期1995年1月23日PCT 1994年5月27日PCT PCT。 第WO94 / 28025号公报 日期1994年12月8日本发明提供了结合细胞表面CD14受体和可溶性CD14受体的单克隆抗体。 该抗体可用于检测样品中细胞表面和可溶性CD14的存在。 进一步提供由上述单克隆抗体产生的嵌合和CDR移植的抗体。 提供含有上述生物组合物的药物组合物。 这些可用于治疗和预防LPS相关疾病，如败血症。
-
公开(公告)号：US06828150B2
公开(公告)日：2004-12-07
申请号：US10266463
申请日：2002-10-08
申请人： Zeling Cai , Jonathan Sprent , Anders Brunmark , Michael Jackson , Per A. Peterson , Alain Luxembourg , Didier J. Leturcq , Ann M. Moriarty
发明人： Zeling Cai , Jonathan Sprent , Anders Brunmark , Michael Jackson , Per A. Peterson , Alain Luxembourg , Didier J. Leturcq , Ann M. Moriarty
IPC分类号： C12N500
CPC分类号： C12N5/0601 , A61K38/00 , A61K2039/5158 , C07K14/005 , C07K14/70503 , C07K14/70539 , C12N5/0636 , C12N15/85 , C12N2501/50 , C12N2501/51 , C12N2502/50 , C12N2502/99 , C12N2760/16122 , C12N2760/18822 , C12N2760/20222 , C12N2830/002 , C12N2830/75 , C12N2830/80 , Y10S530/812 , Y10S530/827
摘要： The present invention relates to synthetic antigen-presenting matrices, their methods of making and their methods of use. One such matrix is cells that have been transfected to produce MHC antigen-presenting molecules and assisting molecules such as co-stimulatory molecules. The matrices can be used to activate CD8+ T-cells to produce cytokines and become cytotoxic.
摘要翻译： 本发明涉及合成抗原呈递矩阵，其制备方法及其使用方法。 一种这样的基质是已被转染以产生MHC抗原呈递分子并辅助分子如共刺激分子的细胞。 该基质可用于激活CD8 + T细胞以产生细胞因子并变成细胞毒性。
-
公开(公告)号：US20090004142A1
公开(公告)日：2009-01-01
申请号：US11782264
申请日：2007-07-24
CPC分类号： C12N5/0636 , A61K38/2013 , A61K38/212 , A61K39/0011 , A61K41/00 , A61K48/00 , A61K2035/124 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , A61K2039/55527 , A61K2039/55533 , A61K2039/55538 , C12N5/0601 , C12N2501/23 , C12N2501/515 , C12N2502/99 , C12N2510/00 , A61K2300/00
摘要： T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen. This artificial antigen expression system can be adapted to treat most cancers in a significant majority of the population.
摘要翻译： 免疫系统受损的人类T细胞反应往往减少。 我们已经开发出一种方法来分离，刺激并扩增能够在体内裂解肿瘤细胞的抗原特异性效应子的初始细胞毒性T淋巴细胞前体（CTLp）。 这种离体协议产生完全功能的效应器。 人类抗原呈递细胞（AAPCs;黑腹果蝇）用人类HLA I类和定义的辅助分子转染，用于刺激来自正常供体和癌症患者的CD8 + T细胞。 在果蝇细胞表面上以高密度表达的I类分子是空的，允许有效负载多个肽，导致产生识别内源表达特定肽的肿瘤细胞的多克隆应答。 如果肽表位是定义的免疫原，所产生的响应是鲁棒的，抗原特异性的和可重复的。 这种人造抗原表达系统可以适应于治疗绝大多数人群中的大多数癌症。
-
公开(公告)号：US09222070B2
公开(公告)日：2015-12-29
申请号：US11782264
申请日：2007-07-24
IPC分类号： C12N5/071 , C12N5/0783 , A61K48/00 , A61K38/20 , A61K38/21 , A61K39/00 , A61K41/00 , C12N5/07 , A61K35/12
CPC分类号： C12N5/0636 , A61K38/2013 , A61K38/212 , A61K39/0011 , A61K41/00 , A61K48/00 , A61K2035/124 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , A61K2039/55527 , A61K2039/55533 , A61K2039/55538 , C12N5/0601 , C12N2501/23 , C12N2501/515 , C12N2502/99 , C12N2510/00 , A61K2300/00
摘要： T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen. This artificial antigen expression system can be adapted to treat most cancers in a significant majority of the population.
-
公开(公告)号：US06461867B1
公开(公告)日：2002-10-08
申请号：US08913612
申请日：1997-09-08
申请人： Zeling Cai , Jonathan Sprent , Anders Brunmark , Michael Jackson , Per A. Peterson , Alain Luxembourg , Didier J. Leturcq , Ann M. Moriarty
发明人： Zeling Cai , Jonathan Sprent , Anders Brunmark , Michael Jackson , Per A. Peterson , Alain Luxembourg , Didier J. Leturcq , Ann M. Moriarty
IPC分类号： C12N506
CPC分类号： C12N5/0601 , A61K38/00 , A61K2039/5158 , C07K14/005 , C07K14/70503 , C07K14/70539 , C12N5/0636 , C12N15/85 , C12N2501/50 , C12N2501/51 , C12N2502/50 , C12N2502/99 , C12N2760/16122 , C12N2760/18822 , C12N2760/20222 , C12N2830/002 , C12N2830/75 , C12N2830/80 , Y10S530/812 , Y10S530/827
摘要： Materials and methods of activating T lymphocytes with specificity for particular antigenic peptides are described, as well as the use of activated T lymphocytes in vitro for the treatment of a variety of disease conditions. In particular, a synthetic antigen presenting matrix for activating T lymphocytes to a specific peptide is described.
摘要翻译： 描述了对特定抗原肽具有特异性活化T淋巴细胞的材料和方法，以及活体T淋巴细胞在体外用于治疗各种疾病状况的用途。 特别地，描述了用于将T淋巴细胞活化到特定肽的合成抗原呈递基质。
-
公开(公告)号：US4777240A
公开(公告)日：1988-10-11
申请号：US648142
申请日：1984-09-07
IPC分类号： G01N33/576 , A61K39/00 , A61K39/29 , C07K7/04 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/02 , C07K14/10 , C07K14/18 , C07K16/00 , C07K16/08 , C12N1/00 , C12N5/00 , C12N5/10 , C12N15/00 , C12N15/09 , C12N15/51 , C12N15/86 , C12P21/00 , C12P21/02 , C12Q1/70 , C12R1/91 , G01N33/53 , G01N33/577 , A61K39/12 , A61K39/42 , C07K15/14
CPC分类号： C07K14/005 , C07K16/082 , C12N15/86 , C12Q1/706 , G01N33/5761 , A61K39/00 , C12N2730/10122 , Y10S435/975 , Y10S436/82 , Y10S530/826 , Y10S930/223
摘要： Cloning and expression vectors for hepatitis B HBxAg, cell cultures containing those vectors, and diagnostic systems and methods for assaying for the presence of HBxAg and anti-HBxAg in a body sample are disclosed.
摘要翻译： 公开了用于乙型肝炎HBxAg的克隆和表达载体，含有这些载体的细胞培养物，以及用于测定身体样品中HBxAg和抗HBxAg的存在的诊断系统和方法。
-
公开(公告)号：US5143726A
公开(公告)日：1992-09-01
申请号：US439099
申请日：1989-11-20
CPC分类号： C07K14/005 , C07K14/00 , A61K39/00 , C12N2730/10122 , Y10S530/806 , Y10S530/807 , Y10S530/826
摘要： Polypeptides corresponding in amino acid residue sequence to T cell stimulating regions of the HBV nucleocapsid protein are disclosed. A method of enhancing the immunogenicity of a polypeptide immunogen comprising operatively linking the polypeptide through an amino acid residue side chain to core protein particles is also disclosed.
摘要翻译： 公开了在氨基酸残基序列中与HBV核衣壳蛋白的T细胞刺激区相对应的多肽。 还公开了增强多肽免疫原的免疫原性的方法，其包括将多肽通过氨基酸残基侧链可操作地连接到核心蛋白颗粒。
-
公开(公告)号：US4818527A
公开(公告)日：1989-04-04
申请号：US939617
申请日：1986-12-09
CPC分类号： C07K7/06 , C07K14/00 , C07K14/005 , A61K39/00 , C12N2730/10122 , Y10S530/806 , Y10S530/807 , Y10S930/223
摘要： Polypeptides corresponding in amino acid residue sequence to T cell stimulating regions of the HBV nucleocapsid protein are disclosed. A method of enhancing the immunogenicity of a polypeptide immunogen comprising operatively linking the polypeptide through an amino acid residue side chain to core protein particles is also disclosed.
摘要翻译： 公开了在氨基酸残基序列中与HBV核衣壳蛋白的T细胞刺激区相对应的多肽。 还公开了增强多肽免疫原的免疫原性的方法，其包括将多肽通过氨基酸残基侧链可操作地连接到核心蛋白颗粒。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.034 秒)
